Daicel Chemical Industries, Ltd. and Groupe Novasep SAS, announce the formation of a strategic technical co-operation aimed at streamlining the use of chiral chromatography to manufacture late-stage clinical and commercial chiral intermediates and APIs.
Under the terms of the agreement, the companies will cooperate to develop the most time and cost-effective solution for the manufacture of chiral compounds for customers in the pharmaceutical industry. Daicel and its subsidiaries, Chiral Technologies Europe SAS and Chiral Technologies Inc., will identify the best chiral stationary phase from their extensive library of commercial and developmental chiral stationary phases (CSP's). Novasep Process will provide process optimisation services, using its unique computer simulation software and full process development with its advanced technologies such as Varicol® continuous chromatography process. The intended result of this combined approach is to deliver guaranteed scale-up, optimum performance and best economics for large-scale separations.